Question to the Foreign, Commonwealth & Development Office:

To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, what steps he plans to take to support the scale up of the provision of long-acting HIV prevention medicines now entering the market.

The UK remains committed to sustainable development goal 3.3 in ending HIV as a public health threat by 2030. Long-acting technologies have the potential to be game-changers in the global response to HIV, but only if they reach the countries and communities that need them most. The UK supports key partners to improve access to long-acting technologies, including Unitaid who recently committed £17 million in market-shaping grants with the Wits Institute in South Africa and Fiotec in Brazil to accelerate affordable access to Lenacapavir.